Preclinical News and Research

RSS

Charité and Samsung Comprehensive Cancer Center partner to advance cancer medicine

Charité – Universitätsmedizin Berlin and the Samsung Comprehensive Cancer Center in Seoul have signed a memorandum of understanding.

31 Jul 2023

Trial evaluates purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

Researchers investigated the safety and pharmacokinetics of JNJ-54175446 in a double-blind, multicenter, randomized controlled trial (RCT).

31 Jul 2023

Two new compounds can block cancer cell’s escape route

Cancer cells are capable of escaping chemotherapy and radiotherapy by activating a signaling pathway that prevents them from dying.

27 Jul 2023

Two infusions of IL-15-expressing CAR NK Cells boost survival in lymphoma mouse models

A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered loss of metabolic fitness in chimeric antigen receptor (CAR) natural killer (NK) cells is a critical mechanism of resistance, with infused cells gradually losing the ability to compete with tumor cells for nutrients, leading to tumor relapse.

26 Jul 2023

KIAA0930 could be a novel therapeutic target for cancer cachexia

A new research paper was published in Oncotarget's Volume 14 on July 20, 2023, entitled, "The uncharacterized transcript KIAA0930 confers a cachexic phenotype on cancer cells."

26 Jul 2023

Advancing vaccine adjuvants: exploring cutting-edge platforms for improved immunization

A group of authors summarized adjuvant mechanisms, characteristics, and applications, seeking to overcome current vaccine limitations.

21 Jul 2023

Researchers develop novel system to identify new therapeutics for familial hypercholesterolemia

The Mona Lisa, painted by the Italian artist Leonardo da Vinci, is one of the most recognizable paintings in the world. But many people would be surprised to learn that this painting offers the first evidence of a disease called familial hypercholesterolemia (FH).

20 Jul 2023

New mRNA-based malaria vaccine shows promise in preclinical trials

Trans-Tasman research collaborators from Te Herenga Waka - Victoria University of Wellington's Ferrier Research Institute and the Malaghan Institute of Medical Research in New Zealand, and the Peter Doherty Institute for Infection and Immunity in Australia have developed an mRNA-based vaccine that can effectively target and stimulate protective immune cell responses against the malaria-causing parasite Plasmodium in preclinical models.

20 Jul 2023

Sense of smell may hold clues to Lewy body pathology: new evidence emerges

Researchers evaluated the impact of Lewy body (LB) positivity (+) on clinical outcomes such as cognition and smell among cognitively.

20 Jul 2023

CEPI and HMRI partner to accelerate development of pandemic vaccines

CEPI, the Coalition for Epidemic Preparedness Innovations, and the Houston Methodist Research Institute (HMRI), have today announced a partnership to combine cutting-edge artificial intelligence (AI) technology with established laboratory techniques to speed up development of future vaccines against novel viral threats (also known as Disease X).

18 Jul 2023

IU researchers present groundbreaking findings at Alzheimer's conference

Researchers from Indiana University School of Medicine had a large presence and leadership role at the 2023 Alzheimer's Association International Conference in Amsterdam, Netherlands, with involvement in more than 150 presentations at the four-day meeting.

18 Jul 2023

An evaluation of the main nanotechnology approaches to improve the therapeutic potential of polyphenols against cancer

Researchers comprehensively evaluated all nanotechnology-based approaches.

18 Jul 2023

AI model accurately predicts which drugs may cause birth defects

Data scientists at the Icahn School of Medicine at Mount Sinai in New York and colleagues have created an artificial intelligence model that may more accurately predict which existing medicines, not currently classified as harmful, may in fact lead to congenital disabilities.

17 Jul 2023

New EULAR points-to-consider can help identify people at risk of psoriatic arthritis

The transition from psoriasis to PsA - and the early diagnosis of PsA - is of considerable scientific and clinical interest. People typically have psoriatic skin disease for a decade or more before they begin to experience the joint involvement of PsA.

17 Jul 2023

Insilico Medicine and MIKADO team up to find new treatments for cystinosis

A team led by researchers at the Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (Zurich, Switzerland) has used Insilico Medicine's generative artificial intelligence (AI) target discovery engine, PandaOmics, to identify actionable drug targets for the lysosomal storage disease cystinosis and to validate them in preclinical models of the disease.

14 Jul 2023

Study suggests anxiety increases the risk of subsequent cognitive progression in non-dementia elderly

Researchers investigate the effects of anxiety on cognitive degeneration in non-dementia elderly.

14 Jul 2023

Difficult transmembrane protein targets for therapeutic antibodies

In this interview, News-Medical talks to Sylvia Xie, product scientist at Sino Biological, about the ongoing emergence of transmembrane proteins as targets for therapeutic antibodies.

From Sino Biological Inc. 12 Jul 2023

Vernal Biosciences Announces Partnership With REPROCELL

Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to provide mRNA services in Japan at scale for research and clinical applications.

From REPROCELL 11 Jul 2023

Imperial spinout NK:IO awarded £1.6M Innovate UK New Cancer Therapeutics grant for development of pioneering NK cell therapy

NK:IO, a leader in NK cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, today announced it has been awarded £1.6M in grant funding from Innovate UK’s New Cancer Therapeutics program.

From NK:IO Limited 11 Jul 2023

Australian rainforest remedies: Scientists explore bioactive plant compounds as potential anti-neuroinflammatory agents

Research discusses the process of discovering anti-inflammatory and neuroprotective drugs from medicinal plants found in the Australian rainforest. It focuses on the pathways from the discovery of bioactive plants to the validation in an appropriate neuro-inflammatory mouse model, using some examples from their current research.

9 Jul 2023

Preclinical News and Research

Charité and Samsung Comprehensive Cancer Center partner to advance cancer medicine

Trial evaluates purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

Two new compounds can block cancer cell’s escape route

Two infusions of IL-15-expressing CAR NK Cells boost survival in lymphoma mouse models

KIAA0930 could be a novel therapeutic target for cancer cachexia

Advancing vaccine adjuvants: exploring cutting-edge platforms for improved immunization

Researchers develop novel system to identify new therapeutics for familial hypercholesterolemia

New mRNA-based malaria vaccine shows promise in preclinical trials

Sense of smell may hold clues to Lewy body pathology: new evidence emerges

CEPI and HMRI partner to accelerate development of pandemic vaccines

IU researchers present groundbreaking findings at Alzheimer's conference

An evaluation of the main nanotechnology approaches to improve the therapeutic potential of polyphenols against cancer

AI model accurately predicts which drugs may cause birth defects

New EULAR points-to-consider can help identify people at risk of psoriatic arthritis

Insilico Medicine and MIKADO team up to find new treatments for cystinosis

Study suggests anxiety increases the risk of subsequent cognitive progression in non-dementia elderly

Difficult transmembrane protein targets for therapeutic antibodies

Vernal Biosciences Announces Partnership With REPROCELL

Imperial spinout NK:IO awarded £1.6M Innovate UK New Cancer Therapeutics grant for development of pioneering NK cell therapy

Australian rainforest remedies: Scientists explore bioactive plant compounds as potential anti-neuroinflammatory agents

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics